“All COVAXIN recipients to be tracked, monitored as if they’re in trial”: Health Minister answers to critics
“All COVAXIN recipients to be tracked, monitored as if they’re in trial”: Health Minister answers to critics: Health Minister Dr Harsh Vardhan responded to opposition’s criticism on the Drugs Controller General of India’s (DCGI) approval for emergency use of the two Indian COVID-19 vaccines - Covaxin and Covishield through a tweet.
"For those spreading rumours let it be known that EUA (Emergency Use Approval) for COVAXIN is differently conditional – in clinical trial mode,” Dr Vardhan tweeted. He also added, "EUA for COVAXIN is different from COVISHIELD because its use will be in clinical trial mode. All COVAXIN recipients to be tracked, monitored as if they’re in trial.”
"COVAXIN approval is ‘Monitored Approval’ with strict follow-up & rolling review. This approval ensures India has an additional vaccine shield in its arsenal esp against potential mutant strains in a dynamic pandemic situation - A strategic decision for our vaccine security (sic),” he said in another tweet.
Prior to this Prime Minister, Narendra Modi in a tweet congratulated the country after the country's drug regulator announced the approval of Pune-based Serum Institute's Covishield and Bharat Biotech's Covaxin, for "restricted use".
Comments
Post a Comment